NewsBenzinga웨드부시, 수트로 바이오파마에 대한 ‘시장수익률 상회’ 의견 재확인 및 목표주가 60달러 유지 웨드부시, 수트로 바이오파마에 대한 ‘시장수익률 상회’ 의견 재확인 및 목표주가 60달러 유지 Benzinga 2026.10.15 13:12 (GMT+0) Open on Benzinga Other news Tennant: An Overvalued Dividend King Facing Margin Pressures (NYSE:TNC) Parker-Hannifin Stock: Wall Street Is Paying Too Much For Quality (NYSE:PH) DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives Kevin O'Leary Says This Is What Sets Elon Musk Apart: 'He Does Not Deal With Noise' Grab Holdings Stock: Strong Multiple-Year Growth Ahead (NASDAQ:GRAB) Ladder Capital Stock: The Case For An Upside Revaluation (NYSE:LADR)
